Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the filgrastim biosimilars market right now?

The market size of filgrastim biosimilars has seen substantial growth over the recent years. It is expected to escalate from $0.92 billion in 2024 to $0.98 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.9%. The expansion during the historic period can be credited to the development of emerging markets, rise in patent expiry, government policies, augmenting healthcare spending, affordable biosimilars, a robust pipeline of medications, and increased investment in biopharmaceutical research and development.

How fast Is the filgrastim biosimilars market expected to grow, and what’s its future value?

In the coming years, the freight forwarding market is projected to experience robust growth. By 2029, it is anticipated to reach a market size of $267.87 billion, with a compound annual growth rate (CAGR) of 5.6%. Several factors contribute to this expected growth during the prediction period, such as AI and data analytics integration, the enlargement of worldwide trade networks, the growth and fulfilment of e-commerce services, a focus on environmentally friendly logistics, and the utilization of self-driving vehicles. The prediction period is also set to see several significant trends, including strategic relationships and alliances, the impact of global economic situations, technological advancements in warehousing, an increase in demand for value-added services, and integrated transportation solutions.

Get your filgrastim biosimilars market report here!

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

What are the leading drivers of growth in the filgrastim biosimilars market?

The growth of the filgrastim biosimilar market is being driven by a rising incidence of neutropenia. Neutropenia is a condition characterized by an insufficient number of neutrophils, key white blood cells that battle infections. Filgrastim biosimilars function by promoting the generation of these neutrophils within the bone marrow, thus boosting the neutrophil count and aiding in the fight against infections. Data from the US-based National Center for Biotechnology Information, a biomedical literature database, from August 2022 indicated a neutropenia prevalence of 0.38% among Mexican-Americans, 0.79% among whites, and a significant 4.5% among black participants. Consequently, the escalating incidence of neutropenia is spurring the expansion of the filgrastim biosimilar market.

What are the key segments defining the filgrastim biosimilars market?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

Who are the key players steering the development of the filgrastim biosimilars market?

Major companies operating in the filgrastim biosimilars market include Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Pfizer, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Fuji Pharma, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios

What emerging trends are influencing the growth of the filgrastim biosimilars market?

Key players in the filgrastim biosimilar market, such as Amneal Pharmaceuticals, are embracing advanced technologies like recombinant DNA technology for the production of biosimilars. This technology involves the creation of hybrid or chimeric DNA by incorporating a foreign sequence into an organism’s DNA. In an example from May 2023, Amneal Pharmaceuticals, based in the US, introduced FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA. Launched in the US, it’s used for the treatment and prevention of febrile neutropenia. FYLNETRA advances the expansion and specialization of neutrophils from specific precursor cells, propels their development, and boosts the longevity and effectiveness of fully evolved neutrophils, causing dosage-dependent increases in neutrophil counts. The introduction of Fylnetra marks a step toward the next generation of cost-effective medicines, enhancing accessibility for patients, healthcare providers, and insurers.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4016

Which regions are most influential in expanding the filgrastim biosimilars market?

North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Trastuzumab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: